The breast cancer detection rate is a benchmark measure of screening mammography quality, but its computation requires linkage of mammography interpretive performance information with cancer incidence data. A Medicare claims-based measure of detected breast cancers could simplify measurement of this benchmark and facilitate mammography quality assessment and research.
C ore measures of mammography performance, such as recall rates and breast cancer detection rates, vary widely across US radiologists and mammography facilities. 1 In addition, despite an average recall rate in the US that is nearly twice that of most European nations, breast cancer detection rates after screening mammography are no higher in the US than in Europe. 2 These findings point to potentially remediable gaps in the quality of US mammography services.
One issue may be differences in radiologist mammography experience and annual interpretive volume in the US versus European countries, 3 and some have suggested benchmarks for screening mammography performance as a means of prompting radiologist-level or facility-level efforts to improve interpretation. 4, 5 The Institute of Medicine has also emphasized the need for high-quality measures of provider-level and facility-level performance to guide targeted quality improvement efforts. 6 The US Medicare program has a particularly large stake in mammography quality improvement. Medicare pays for over 8.5 million mammograms each year at a cost of over $1 billion annually, 7 and over half of incident breast cancers occur among women older than 65 years. 8 Currently, Medicare reports facilitylevel performance of follow-up or recall rates as part of the Hospital Quality Reporting Program. However, additional valid and reliable performance measures are needed to facilitate broader scale improvement.
Medicare claims data are one potential data source for measuring mammography interpretative performance. The breast cancer detection rate, for example, is a widely used measure of radiologist-level and facility-level interpretive performance; a cancer detection rate of 2.5 breast cancers per 1000 screening mammograms is considered a minimally acceptable performance level. 5 This measure, however, is challenging to implement, because it requires accurate identification of: (1) screening mammograms; (2) subsequent incident breast cancers; and (3) screening mammography interpretation. With regard to identifying screening mammograms using Medicare data, we recently validated a claims-based algorithm for distinguishing screening from diagnostic mammograms. 9 The distinction between screening and diagnostic is critical, because the incidence of breast cancer is much higher following diagnostic than screening mammography. 4,10 However, with regard to the second step, there has been uncertainty about the accuracy of claims for identifying incident (rather than prevalent) breast cancers. 11, 12 Diagnosis codes for breast cancer are not specific for incident rather than prevalent disease, and procedure codes for breast cancer treatments, such as mastectomy, can occur when women are treated for either benign conditions or recurrent breast cancer. Finally, claims provide no direct information to infer whether mammograms were interpreted as normal or abnormal, potentially limiting the ability to infer that incident cancers were detected at screening mammography.
Nattinger et al 13 previously validated a clinically informed, 4-step algorithm for distinguishing incident from prevalent breast cancers using Medicare claims data. Relative to a reference standard based on Surveillance, Epidemiology, and End Results (SEER) cancer registry data, the algorithm achieved a sensitivity of B80% and a positive predictive value (PPV) of over 90%. However, the algorithm was not validated in a cohort undergoing screening mammography, so it is uncertain if the algorithm accurately identifies breast cancers in a screening population, nor does the algorithm address screening mammography interpretation. In addition, the algorithm was validated using data from 1994, and it is uncertain if it achieves similar performance with more recent Medicare claims.
We capitalized on the linkage of high-quality mammography and cancer incidence data from the Breast Cancer Surveillance Consortium (BCSC) with Medicare claims to evaluate the performance of claims-based methods for identifying incident breast cancer that followed positive screening mammography. We first assessed the performance of the approach described by Nattinger et al 13 within a screening mammography cohort. (Henceforth, we refer to this as the Nattinger algorithm.) We then assessed whether classification and regression tree (CART) analyses could identify an alternative approach with improved performance. We hypothesized that claims-derived algorithms could identify incident cancers following true-positive screening mammography with high predictive value in recent Medicare claims.
METHODS

Data
We used data from Medicare claims files (the Carrier Claims, Outpatient, and Inpatient files) and the Medicare denominator file, which provides demographic, enrollment, and vital status data. Although Medicare mammography claims typically appear in the Carrier file, we assessed both the Carrier and Outpatient files to capture the minority of claims present only in the Outpatient file (B3%). 14 We used Healthcare Common Procedure Coding System procedure codes to identify bilateral mammograms and procedures occurring before and after mammography. Medicare claims also include International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-CM) diagnosis codes, which we used to identify breast cancer diagnosis codes and breast symptoms.
Medicare claims from 1998 to 2006 were linked with BCSC mammography data derived from regional mammography registries in 4 states (NC; San Francisco Bay Area, CA; NH; and VT) (http://breastscreening.cancer.gov/). Claims and BCSC mammography data were matched using a deterministic algorithm derived by the National Center for Health Statistics that is based on social security numbers (when available), names, and birthdates. Among women aged 65 years and older with a BCSC mammogram between 1998 and 2006, 87% were successfully matched to Medicare claims. Women who did not successfully match typically received mammography at facilities that did not report social security numbers to the BCSC.
BCSC facilities transmit prospectively collected patient and mammography data to regional registries, which link the data to breast cancer outcomes ascertained from regional or statewide cancer registries and pathology data. Data are pooled at a central Statistical Coordinating Center (SCC). BCSC mammography data include information on examination purpose (screening vs. diagnostic), radiologist interpretation, and patient sociodemographics and breast health history. The BCSC has established standard definitions for key variables and multiple levels of data quality control and monitoring. 15 Each registry and the SCC have received institutional review board approval for either active or passive consenting processes or a waiver of consent to enroll participants, link data, and perform analytic studies. All procedures are Health Insurance Portability and Accountability Act compliant and all registries and the SCC have received a Federal Certificate of Confidentiality to protect the identities of patients, physicians, and facilities.
Subjects
We identified mammograms captured in both Medicare claims and the BCSC among women who were aged 68 or older on mammography dates from January 1, 2001 to December 31, 2005. We identified screening mammograms (distinguishing them from diagnostic mammograms) using a validated claims-based algorithm based upon the Healthcare Common Procedure Coding System mammogram codes, claims for mammography in the previous 9 months, and claims with ICD-9-CM codes for breast cancer during the year before mammography. 9 Relative to a BCSC-derived reference standard, the PPV of the algorithm's screening designation was B95%. We used the claims-based algorithm (rather than BCSC data) to identify screening mammograms so that results would be potentially generalizable to other Medicare claims-based studies where linkage of claims to mammography registry data is not feasible.
We selected mammograms for women with continuous enrollment in fee-for-service Medicare (parts A and B) for 12 months after mammography and 3 years before mammography, enabling both prospective assessment of outpatient claims for clinical events that might indicate incident breast cancer following abnormal screening mammography, and retrospective assessment for claims indicating prevalent breast cancer. Hence, we excluded women aged 65 to 68 years because only women aged 68 years or greater consistently have 3 years of prior claims. Following Nattinger et al, 13 we considered a woman to have prevalent cancer if any ICD-9-CM codes for invasive breast cancer or ductal carcinoma in situ appeared on claims in the 3 years before mammography (see Table, Supplemental Digital Content 1, http://links.lww.com/MLR/A530, which gives claims and diagnostic codes used in developing study variables). Although some women with prevalent breast cancer continue to receive screening mammography, we excluded these mammograms so that our sample represented women undergoing screening who had no breast cancer in the prior 3 years. We randomly divided the sample into 2 half-samples, 1 for training and 1 for validation of CART analyses.
Reference Standard
We used BCSC cancer registry data to identify incident breast cancers and BCSC mammography data to identify radiologists' mammography interpretation. We defined incident breast cancers as those with a diagnosis date within 1 year of the date of screening mammography. Following standard BCSC definitions (http://breastscreening.cancer. gov/data/bcsc_data_definitions.pdf), a positive mammogram was defined as one with a Breast Imaging Reporting and Data System assessment of 0 (needs additional imaging evaluation), 3 (probably benign finding) with a recommendation for immediate follow-up, 4 (suspicious abnormality), or 5 (highly suggestive of malignancy). 16 Mammograms with other Breast Imaging Reporting and Data System assessments were defined as negative, because no immediate evaluation was recommended at the time of screening mammography. A screen-detected breast cancer was defined as a positive mammogram with a diagnosis of incident breast cancer within 1 year.
Claims-based Algorithms for Identifying Incident Screen-detected Breast Cancers
We first adapted the Nattinger algorithm to identify incident breast cancers during the 1 year following screening mammography. 13 The Nattinger algorithm begins by identifying "high-probability" cases based on codes for breast cancer diagnoses and therapies during the year following the index date (in this instance, the date of mammography). Next, the algorithm attempts to exclude women treated for benign breast disease, cancers that were metastatic to the breast, and, finally, women with prevalent breast cancer based on breast cancer diagnosis codes occurring during 3 years of claims before the index date. We classified all cases identified by the algorithm as screen-detected incident cancers. Although we recognize that the Nattinger algorithm was not designed to consider mammography interpretation, we felt that it was valuable to evaluate its performance in the context of recent screening mammography.
We then conducted CART analyses in attempts to identify an algorithm with improved performance. 17 CART is a nonparametric decision tree methodology that identifies sequential binary partitions in independent variables to optimize prediction of the dependent variable (in this case, incident breast cancer detected at screening mammography). A potential advantage is that CART can specify the bestperforming time intervals for ascertaining breast cancer diagnosis or treatment codes following incident breast cancers that were detected at mammography.
Potential independent variables for CART analyses were derived from claims on the mammogram date or during a 1-year postmammogram follow-up, including: patient age; days to any subsequent mammogram; days to diagnosis codes for breast cancer, ductal carcinoma in situ, benign breast tumors, secondary cancers of the breast, or a personal history of breast cancer; days to procedural or diagnostic codes for breast biopsies; days to any procedural codes for breastdirected surgery (lumpectomy, partial mastectomy, or mastectomy), axillary lymph node biopsy or resections; and days to any codes for breast radiation. 18 We performed CART analyses on the training halfsample of mammograms. The CART algorithm selected splits in independent variables on the basis of the Gini index, and continued growing the tree until no further splits improved the Gini index by >0.0001. 17 To minimize overfitting, we pruned the tree to optimal complexity based on crossvalidation.
Analyses of Classification Accuracy
Within the validation subsample, we created crosstabulations to compare the identification of incident screendetected breast cancers using claims-based algorithms versus the reference standard. We quantified accuracy using: sensitivity (the proportion of incident screen-detected cancers that were identified by the algorithm); specificity (the proportion of mammograms without incident screen-detected cancers that were so classified by the algorithm); PPV (the proportion of algorithmically identified incident screendetected cancers that were also classified as such by the reference standard); and negative predictive value (the proportion of mammograms classified as having no incident screen-detected cancer also classified as having no incident screen-detected cancer by the reference standard). As a practical test of the algorithm's accuracy, we compared unadjusted relative rates of breast cancer detection as computed using the CART algorithm and BCSC data (ie, the reference standard) within subgroups based on age, race/ethnicity, nonurban versus urban residence, and Medicaid eligibility. A woman was classified as Medicaid eligible if the Medicare denominator file indicated at least 1 month of Medicaid eligibility in the 3 years before or 1 year after the index mammogram. Nonurban versus urban residence was determined using the Rural Urban Commuting Area Code for the zip code of the woman's primary residence. We computed 95% confidence intervals around all point estimates. We performed statistical analyses using the rpart package in R, version 2.12.0 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Mammogram Samples
We identified a sample of 233,044 screening mammograms with linked Medicare claims and BCSC records. The mammograms were obtained from 104,997 women who received an average of 2.2 mammograms during the study period (range, 1-7). On the date of mammography, women had a mean age of 75.2 years (SD = 5.3; range, 68-104). On the basis of BCSC interpretation and cancer data, radiologists detected breast cancer on 1384 of the mammograms; the breast cancer detection rate in the sample was 5.9 cancers per 1000 screening mammograms. The patient sample was ethnically diverse with substantial representation in both nonurban and urban settings ( Table 1 ).
Performance of Claims-based Algorithms
Using CART analyses, we identified a claims-based algorithm that classified women based on whether breast cancers were detected as screening mammography (Fig. 1) . Assessing claims for 1 year following screening mammography, the algorithm classifies a mammogram as having detected breast cancer if there is a claim diagnosis code for breast cancer within 123 days and any claim for breastdirected surgery within 1 year. Alternatively, if there is no claim diagnosis code for breast cancer within 123 days, the algorithm classifies a mammogram as having detected incident breast cancer if there is a claim diagnosis code for ductal carcinoma in situ within 286 days and a claim for another mammogram within 82 days. The algorithm classifies all other mammograms as not detecting incident breast cancer. (See Supplemental Digital Content 2, http://links. lww.com/MLR/A531 for programming code for implementing the algorithm in R.)
We compared the performance of the Nattinger algorithm and the CART-derived algorithm in identifying incident breast cancer detected at screening mammography ( Table 2) . Although the Nattinger algorithm had a sensitivity In analyses stratified by age, race/ethnicity, Medicaid eligibility, and nonurban versus urban residence, estimates of relative rates of incident-detected breast cancer using the algorithm were similar to reference standard estimates based on BCSC data (Table 3) .
DISCUSSION
In a sample of screening mammograms with corresponding Medicare claims and mammography registry data, a claims-based algorithm identified screening mammograms with detected incident breast cancers with a sensitivity > 90%, a specificity over 99.9%, and a PPV of 88%. Algorithm performance was generally similar across population subgroups and enabled accurate estimates of between-group relative rates of incident breast cancer detection.
Both the CART-derived algorithm and the algorithm proposed by Nattinger et al 13 had very high specificities compared with the BCSC-derived reference standard. A high specificity is crucial for a cancer detection algorithm. With a rare outcome such as breast cancer, even a slight decrement in specificity could markedly diminish the measure's PPV, as the number of false-positives may quickly accumulate in comparison with the number of true-positives. Nevertheless, sensitivity is also important to PPV. In this screening mammography cohort, the PPV of the CART approach (88.0%) exceeded that of the Nattinger approach (77.5%) due to a combination of slightly higher specificity and higher sensitivity (93.9% vs. 83.7%).
The PPV of 88.0% for the CART approach implies that approximately 1 of 9 cancers identified by the algorithm as incident-detected breast cancers are wrongly identified as such. In the validation set, this included 87 cases (of a total 116,522 mammograms). As shown in Figure 1 , most of these false-positives occurred among women with breast cancer diagnosis codes within 123 days and breast-directed surgery within 1 year of screening mammography. Using BCSC data, we found that B36% (n = 31) of these women had interval breast cancers that were not detected at screening mammography yet were diagnosed clinically within 365 days of screening. In addition, we found that a small fraction of examinations (< 13%) had breast cancer diagnosis codes on claims but ultimately had benign biopsy results; providers for these women may have used breast cancer diagnosis codes while "ruling out" breast cancer. (Specific numbers suppressed to protect subject confidentiality.) Despite exclusion of mammograms for women with breast cancer diagnosis codes on claims during the 3 prior years, a small fraction of mammograms (< 13%) were performed on women with prevalent breast cancers based on BCSC data and who received breastdirected surgery during the year following screening mammography, conceivably for local recurrences. Meanwhile, the algorithm did not identify 7.1% of women whose breast cancers were truly detected at mammography (49 of 689 detected incident cancers in the validation set). As shown in Figure 1 , many of these women may have had delays in the appearance of diagnostic codes for invasive breast cancer or ductal carcinoma in situ or delays in receipt of either breast-directed surgery or subsequent mammography. Nattinger et al 13 similarly found that a small fraction of women with incident breast cancer according to SEER data did not receive breast cancer surgery; these women were more likely than women who received surgery to lack breast cancer diagnostic codes in Medicare claims. We recognize that the cut-points in the CART algorithm may seem arbitrary, such as the initial node in which a breast cancer diagnosis code is assessed as occurring within 123 days of screening mammography. Although there is no clinical justification for this cut-point, it yields the optimal classification of cases as assessed by the Gini index and validated in a testing subsample. Thus, a shorter or longer cut-point would compromise overall classification accuracy, most likely with degradation in PPV. At the same time, we believe the general structure and flow of the decision tree is clinically intuitive as one would expect diagnosis codes for breast cancer with subsequent procedure codes for treatment to be reliable predictors of incident breast cancer. The assessment for procedure codes for subsequent mammography among women with diagnosis codes for ductal carcinoma in situ is perhaps less intuitive, although most women with newly diagnosed ductal carcinoma in situ will indeed receive diagnostic mammography within 82 days of screening mammography.
Several potential uses of the CART algorithm are conceivable. First, the algorithm may be useful in claimsbased studies of screening mammography outcomes, including studies of new screening technologies, such as digital mammography or computer-aided detection, on incident breast cancer detection. Because the algorithm does not require linkage with cancer registry data, investigators may apply it in unlinked Medicare claims, enabling sample sizes that would not be achievable with linked data such as the SEER-Medicare data. Second, the algorithm could conceivably enable claims-based estimation of radiologist-level or facility-level quality metrics, specifically breast cancer detection rates, facilitating quality improvement efforts in mammography among Medicare enrollees. We recognize that the algorithm's PPV of B88% does not confer certainty regarding a provider's true-positive interpretation. The algorithm may nevertheless allow identification of the providers with extremely low breast cancer detection rates. In any application, investigators must carefully consider potential impacts of algorithmic misclassification on study results and plan suitable sensitivity analyses.
Although BCSC data on whether breast cancers were detected at mammography may be imperfect, leading to inaccuracy in the reference standard, the BCSC mammography data undergo rigorous quality control and are linked with high-quality regional cancer registries. Our results also derive from mammography claims of fee-for-service Medicare enrollees within 4 US regional mammography registries. Algorithms may not generalize to non-Medicare claims or to Medicare enrollees outside these regions. Because study algorithms require 3 years of prior claims to exclude prevalent breast cancers, their validity among women younger than age 68 years is uncertain. We also recognize that CART analyses may be prone to overfitting. Nevertheless, our analysis included variables that are clinically meaningful, and we cross-validated the CART-derived algorithm within the training sample. We also pruned the tree based on theory and practice, and the final tree was highly predictive in the test sample. Finally, in late 2014, Medicare will transition from ICD-9 to ICD-10 coding. While the mapping of the algo-rithm's breast cancer diagnosis and procedure codes should be unambiguous, the performance of the algorithm would ideally be reevaluated after the transition to ICD-10.
Study strengths include the inclusion of large mammography claim samples from geographically diverse settings that were linked with high-quality external mammography data, yielding rigorous validation analyses with excellent precision. Because cancer registries such as SEER encompass only 25% of the US population, 20 the alternative algorithms may enable mammogram sampling for research or quality improvement across the entire Medicare program regardless of claims linkage with cancer registry data.
We found that a simple, Medicare claims-based algorithm can identify with high predictive value women with incident breast cancers following a positive screening mammogram. Applied to Medicare claims alone without cancer registry linkage, the algorithm may be useful in claims-based studies of screening mammography. The potential for using the algorithm in provider-level quality assessment warrants evaluation.
